Skip to main content

Generics

  • Hospira reports mostly flat sales in Q2 2013

    LAKE FOREST, Ill. — Hospira posted sales of $1 billion during second quarter 2013, a 0.7% decrease compared with second quarter 2012, the generic drug maker said.

    Hospira, which specializes in making generic injectables, also posted $318.7 million gross profit, a 12.4% increase over second quarter 2012's $283.5 million.

  • Mylan sales, profits increase in second quarter 2013

    PITTSBURGH — Mylan's sales ticked up slightly in second quarter 2013, compared with the same period last year, the company said.

    The Pittsburgh-based generic drug maker reported sales of $1.7 billion, a 1% increase over second quarter 2012's $1.69 billion. For the six-month period that ended June 30, sales were $3.33 billion, a 2% increase over $3.27 billion during the same period last year.

  • FDA approves Lupin angina drug

    BALTIMORE — The Food and Drug Administration has approved a generic heart disease drug made by Lupin, the Indian drug maker said.

    Lupin said the FDA approved its ranolazine extended-release tablets in the 500-mg and 1,000-mg strengths. The drug is used to treat chronic angina.

    Ranolazine extended-release tablets are a generic version of Gilead Sciences' Ranexa, which had sales of about $443.4 million during the 12-month period that ended in March, according to IMS Health.

     

  • Amneal introduces generics for HIV, potassium deficiency, other conditions

    BRIDGEWATER, N.J. — Amneal Pharmaceuticals has introduced five new generic drugs, the company said.

    The drugs launched are:

    Potassium chloride extended-release capsules in the 750-mg strength and in bottle count sizes of 100, 500 and 1,000. The drug is a generic version of Nesher Pharmaceuticals' Micro-K10 ExtenCaps and used to treat potassium deficiency.

    Sildenafil tablets in the 20-mg strength and in 90-count bottles. The drug is a generic version of Pfizer's Revatio, used to treat pulmonary arterial hypertension.

  • Senate puts off vote for track-and-trace, compounding bill

    NEW YORK — The Senate was expected to take up a bill designed to secure the drug supply chain and establish a list of "do not compound" medications, but left for recess Friday without voting on it.

  • FDA approves Perrigo's fluticasone propionate lotion

    ALLEGAN, Mich. — The Food and Drug Administration has approved a Perrigo generic drug for treating dermatitis, the company said Wednesday.

    Perrigo announced the FDA approval of fluticasone propionate lotion in the 0.05% strength. The drug is a generic version of Fougera Pharmaceuticals division PharmaDerm's Cutivate and is used to treat inflammatory and pruritic manifestations of atopic dermatitis in patients ages 1 year and older.

    The drug has annual sales of about $19 million, according to Symphony Health Solutions.

     

  • Lupin receives tentative approval for generic sleeping, rosacea drugs

    BALTIMORE — The Food and Drug Administration has given Lupin Pharmaceuticals tentative approval to two of its products, the company said Wednesday.

    Lupin announced the tentative approvals for armodafinil tablets in the 50-mg, 100-mg, 150-mg, 200-mg and 250-mg strengths and doxycycline capsules in the 40-mg strength. Tentative approval means that the drugs meet the FDA's conditions for approval, but can't be marketed yet due to patent or market exclusivity protection that has yet to expire.

  • Perrigo to buy Elan Corp.

    ALLEGAN, Mich. — U.S.-based drug maker Perrigo Co. will buy Ireland's Elan Corp. for $8.6 billion, the companies said Monday.

    Elan is best known for the multiple sclerosis treatment Tysabri (natalizumab), marketed and distributed by Biogen Idec. Perrigo manufactures various branded and generic prescription and OTC drugs. A previously announced deal, whereby New York-based Royalty Pharma would acquire the Dublin-based drug maker, fell apart last month after Elan shareholders voted in favor of a share-buyback plan.

X
This ad will auto-close in 10 seconds